An innovative drug for Alzheimer's disease from China at the end of Phase 3 clinical trials
Friday, July 20, 2018
Shanghai Green Valley Pharmaceutical Co., Ltd today announced that Phase 3 trials for Sodium Oligomannurarate (GV-971) capsules used in mild to medium-sized cases Alzheimer's disease reached the first endpoint.
Randomized, double-blind clinical trials with placebo in China aimed to assess the safety and efficacy of GB-971, an oligosaccharide drug with multilateral targeting. Patients with mild to moderate Alzheimer's disease (MMSE score 11 to 26) were included in the study. Regarding treatment, patients received 450 mg of GV-971 orally twice daily for 36 weeks. The first endpoint showed a better change in the cognitive scale of Alzheimer's disease (the so-called ADAS-cog) after 36 weeks of taking GV-971 compared to the placebo control group. The data showed that substance GV-971 contributed to a significant improvement in cognitive function problems. Regarding side effects,
Alzheimer's disease is a chronic neurodegenerative disease characterized by progressive loss of cognitive function. According to Alzheimer's Disease International, around 48 million patients suffer from Alzheimer's disease worldwide, and this number is expected to rise to 130 million by 2050 due to the aging population.
Later this year, Green Valley plans to apply for permission to promote GV-971 in the treatment of mild to moderate Alzheimer's cases issued by the Chinese Office for Drug Administration.
